ABC Arbitrage SA Buys Shares of 2,120 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ABC Arbitrage SA purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,120 shares of the biopharmaceutical company's stock, valued at approximately $1,510,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at about $37,000. Private Wealth Management Group LLC raised its position in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $39,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.8 %

REGN stock traded up $5.66 during trading on Wednesday, reaching $685.66. 638,281 shares of the stock traded hands, compared to its average volume of 938,896. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The business's 50 day moving average price is $702.67 and its 200-day moving average price is $889.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market capitalization of $74.96 billion, a PE ratio of 17.91, a P/E/G ratio of 2.26 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm earned $11.86 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.51%. The ex-dividend date is Thursday, February 20th.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Royal Bank of Canada lowered their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a report on Friday, November 1st. Evercore ISI dropped their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.